BeOne Medicines (NASDAQ:ONC – Get Free Report) and Cosmos Health (NASDAQ:COSM – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.
Profitability
This table compares BeOne Medicines and Cosmos Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BeOne Medicines | 1.38% | 5.52% | 3.17% |
| Cosmos Health | -31.01% | -33.19% | -13.65% |
Analyst Recommendations
This is a breakdown of current ratings for BeOne Medicines and Cosmos Health, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BeOne Medicines | 1 | 1 | 13 | 0 | 2.80 |
| Cosmos Health | 1 | 0 | 0 | 0 | 1.00 |
Volatility and Risk
BeOne Medicines has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, Cosmos Health has a beta of 5.37, meaning that its share price is 437% more volatile than the S&P 500.
Earnings & Valuation
This table compares BeOne Medicines and Cosmos Health”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BeOne Medicines | $3.81 billion | 10.07 | -$644.79 million | $0.51 | 686.27 |
| Cosmos Health | $54.43 million | 0.32 | -$16.18 million | ($0.75) | -0.63 |
Cosmos Health has lower revenue, but higher earnings than BeOne Medicines. Cosmos Health is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 12.6% of Cosmos Health shares are held by institutional investors. 6.6% of BeOne Medicines shares are held by company insiders. Comparatively, 25.1% of Cosmos Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
BeOne Medicines beats Cosmos Health on 11 of the 14 factors compared between the two stocks.
About BeOne Medicines
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
About Cosmos Health
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors. It sells its products through independent wholesale distributors. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.
Receive News & Ratings for BeOne Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeOne Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
